Pegasus Biotech Inc., a full-service biotechnology contract research organization, has announced the development of BPE plasmid technology. This technology allows for the precise control of DNA replication, enabling higher levels of expression and reduced costs compared to existing methods. The BPE plasmid utilizes a patented origin that can lay dormant during fermentation and trigger replication at high cell densities, resulting in up to seven times more expression than conventional plasmid backbones.
Daniel Wilson, COO of Pegasus Biotech, emphasized the transformational nature of this technology, especially in applications where cost of goods sold and patient safety are critical factors. The project required low cost, minimal bacterial sequences, high expression, and no antibiotic resistance selection marker – all of which are characteristics of this technology.
Pegasus Biotech specializes in vaccine and biopharmaceutical development and offers seed-to-formulation process development and associated analytical development services to clients worldwide. Their services ensure that client projects comply with global regulations and result in commercially viable products. For more information on Pegasus’ services, visit their website.
The BPE plasmid technology is expected to have significant implications for the biopharmaceutical industry as it offers a more efficient and cost-effective way to produce DNA vaccines and biopharmaceuticals. Pegasus Biotech aims to facilitate the development and market entry of innovative biopharmaceutical and vaccine products through this new technology.